Dong-A ST Signs License-out Deal with Polifarma of Türkiye for NESP® Biosimilar DA-3880
UPPSALA, Sweden, Sept. 6, 2022 /PRNewswire/ -- Dong-A ST Co., Ltd. (170900: Korea SE), a Korean pharmaceutical company, and Beactica Therapeutics AB, a Swedish precision oncology company, today announced that they have mutually agreed to terminate their collaboration and licensing agreement. The collaboration focused on developing novel candidate compounds against multiple cancer targets of mutual interest. The partnership has been productive, and multiple compound classes are now in various stages of lead generation and optimization.
Dong-A ST Co., Ltd., a Korean pharmaceutical company, and Beactica Therapeutics AB, a Swedish drug discovery company, have announced that a lead compound meeting certain pre-defined criteria has been selected in their collaborative research programme aimed at developing first-in-class protein-protein interaction inhibitors for a target of therapeutic importance in cancer and other diseases.
SEOUL, South Korea and UPPSALA, Sweden, 12 March ,2019 /PRNewswire/ -- Dong-A ST Co., Ltd. (170900: Korea SE), the Korean pharmaceutical company, and Beactica AB, the Swedish drug discovery company, today announced an expansion of their research and licensing agreement. The collaboration - which was initiated in October 2016 - is now expanded with an aim to jointly identify and develop novel small molecules targeting a protein-protein interaction of therapeutic relevance for immuno-oncology. The partnership further builds on Beactica's unique early-stage lead generation capabilities and DONG-A ST's strengths in the pharmacological proof of novel target concepts as well as downstream pre-clinical and clinical development of new therapeutic agents.
Japan's Kaken Pharmaceutical Co Ltd has announced that the company and Dong-A ST Co Ltd, headquartered in Seoul, Korea concluded an exclusive distribution agreement for Clenafin/Jublia, which is a topical formulation for treatment of Onychomycosis in Korea.